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Abstract
Rationale—Amisulpride is approved for clinical use in treating schizophrenia in a number of
European countries and also for treating dysthymia, a mild form of depression, in Italy. Amisulpride
has also been demonstrated to be an antidepressant for patients with major depression in many clinical
trials. In part because of the selective D2/D3 receptor antagonist properties of amisulpride, it has long
been widely assumed that dopaminergic modulation is the proximal event responsible for mediating
its antidepressant and antipsychotic properties.
Objectives—The purpose of these studies was to determine if amisulpride’s antidepressant actions
are mediated by off-target interactions with other receptors.
Materials and Methods—We performed experiments that: (1) examined the pharmacological
profile of amisulpride at a large number of CNS molecular targets and (2) after finding high potency
antagonist affinity for human 5-HT7a serotonin receptors, characterized the actions of amisulpride
as an antidepressant in wild-type and 5-HT7 receptor knock-out mice.
Results—We discovered that amisulpride was a potent competitive antagonist at 5-HT7a receptors
and that interactions with no other molecular target investigated here could explain its antidepressant
actions in vivo. Significantly, and in contrast to their wildtype littermates, 5-HT7 receptor knockout
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Conclusions—These results indicate that 5-HT7a receptor antagonism, and not D2/D3 receptor
antagonism, likely underlies the antidepressant actions of amisulpride.
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Introduction
Amisulpride is a benzamide derivative that was initially developed as a selective D2/D3
receptor antagonist for the treatment of schizophrenia (Perrault et al. 1997). Amisulpride has
been shown to be as or more effective than various comparators in the treatment of
schizophrenia in a large number of clinical trials (Racagni et al. 2004). Meta-analyses have
identified clozapine, amisulpride, risperidone, and olanzapine as being significantly more
effective than first generation (typical) antipsychotics and other second generation (atypical)
antipsychotics (Davis et al. 2003), (Leucht et al. 2009). Clinically, amisulpride is characterized
by a side effect profile most resembling that of an atypical antipsychotic, due to its low
extrapyramidal symptom (EPS) burden (Leucht et al. 2002). However, like risperidone and
first generation antipsychotic drugs, amisulpride causes large elevations in serum prolactin
levels, most likely due to its potent D2/D3 antagonist properties (Wetzel et al. 1998). Thus,
despite having a pharmacological profile reminiscent of a typical antipsychotic in that it
exhibits high D2 affinity and low 5-HT2A affinity, amisulpride therapeutically resembles
atypical antipsychotics. Amisulpride has also been reported to improve the cognitive domains
of attention, executive function, and working memory, as well as the global cognitive index in
patients with schizophrenia (Deeks and Keating 2008), and declarative memory in another
study (Mortimer et al. 2007). However, it has also been shown to impair recognition memory
in normal subjects (Gibbs et al. 2008), (Mortimer et al. 2007).
Interestingly, there is evidence that amisulpride has antidepressant properties in both
schizophrenia (Kim et al. 2007) and other psychiatric disorders (Montgomery 2002).
Amisulpride is approved for treating dysthymia in Italy (Pani and Gessa 2002) and has been
shown to be a highly effective antidepressant (Montgomery 2002). In fact, amisulpride has
been shown to as effective as imipramine in patients with dysthymia and major depression, as
measured by the Montgomery and Asberg Depression Rating Scale (MADRS) (Lecrubier et
al. 1997). In another study, amisulpride was as effective as fluoxetine in treating major
depression and dysthymia (Smeraldi 1998). Amisulpride was also similar to fluoxetine in terms
of the percent of subjects with dysthymia or major depression who responded to treatment, the
number of adverse events, and dropout rates (Smeraldi 1998). In fact, amisulpride has been
shown to be as effective as comparator in humans in at least six clinical studies in patients with
dysthymia and/or major depression (Racagni et al. 2004).
The presumed selectivity of amisulpride for D2 and D3 dopamine receptors has led to the
prevailing hypothesis that modulation of dopaminergic signaling is responsible for its
antidepressant efficacy. Indeed, a role for dopamine in antidepressant action is plausible.
Multiple antidepressants from different classes, including fluoxetine, fluvoxamine, and
desipramine, increase extracellular dopamine in the prefrontal cortex of rats (Tanda et al.
1994), (Jordan et al. 1994), (Bymaster et al. 2002). On the other hand, sulpride, another
benzamide derivative with selectivity for D2/D3 receptors, significantly reduces the
antidepressant efficacy of desipramine in the forced swim test in rats when bilaterally injected
into the nucleus accumbens, but not the caudate putamen (Cervo and Samanin 1987).
Furthermore, although it has been suggested that sulpride has antidepressant effects in humans,
its efficacy in this regard was found to be much smaller than that seen with the comparator,
amitryptiline (Drago et al. 2000). Overall, with the exception of amisulpride, none of the
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benzamides are well established as exhibiting antidepressant activity comparable to serotonin
reuptake inhibitors (SSRIs) and tricyclics.
While the evidence is strong that some antidepressants can modulate dopaminergic systems,
there is little or no evidence, other than the aforementioned phenomenological data, that
selective dopamine receptor antagonists such as haloperidol have antidepressant effects as
monotherapy absent action at any other targets. For instance, aripiprazole is approved for
adjunctive treatment of depression although it has significant off-target actions at many
biogenic amine receptors and transporters implicated in antidepressant drug actions (Shapiro
et al. 2003). Olanzapine has also been shown to be an effective adjunctive agent to
antidepressants in some studies with treatment resistant or bipolar depression (Deeks and
Keating 2008). Additionally, quetiapine’s antidepressant actions are most likely due to potent
inhibition of the norepinephrine transporter by its main metabolite N-desalkyl-quetiapine
(Jensen et al. 2008) and not to any direct actions on dopamine receptors. Thus, we set out to
test the hypothesis that the antidepressant action of amisulpride results from D2/D3 receptor
antagonism. We screened amisulpride at a large number of CNS targets in the hopes of
identifying and then characterizing target(s) responsible for its antidepressant actions.
Materials and Methods
Radioligand binding assays
Radioligands were purchased from Perkin-Elmer or GE Healthcare. Competition binding
assays were performed using transfected or stably-expressing cell membrane preparations as
previously described (Shapiro et al. 2003), (Roth et al. 2002) and are available on-line
(http://pdsp.med.unc.edu). Key information such as radioligand identity, radioligand
concentration, incubation buffer, and incubation time are in Table 1 and additional information
is available on-line (http://pdsp.med.unc.edu/UNC-CH$20Protocol%20Book.pdf).
Schild analysis
Cells stably expressing 5-HT7a receptors were sub-cultured into a 96 well white OptiPlate 96
(Perkin-Elmer) at 10,000 cells per well in DMEM with 1% dialyzed FBS overnight. Culture
media was removed and replaced with assay media (DMEM containing 2 mM IBMX and 10
mg/100 ml ascorbic acid) for 30 minutes at 37°C. The pre-incubation media was then aspirated
off, and 5 µL/well of amisulpride in the above assay media was added at 10X of the final
concentrations (0, 1, 3, 10, 30, 100, and 300 nM). Five minutes later, 5 µL/well of 5-HT was
added at 10X of the final concentrations (0, 3, 10, 30, 100, 300, 1000, and 3000 nM). The assay
was designed to generate a 5-HT dose-response curve in duplicate in the absence and presence
of increasing concentrations of amisulpride at every concentration point. The reaction
proceeded for 30 minutes at 37°C. The cAMP production was determined with GE's HitHunter
cAMP XS+ kit according to the manufacturer's instruction. Briefly, at the end of 30min
reaction, cAMP antibody reagent was added, immediately followed by a mixture of Galacton-
Star, Emerald-II, lysis buffer and cAMP XS+ ED reagent at a 1:5:19:25 ratio. After a one hour
incubation at room temperature, the cAMP XS+ EA reagent was added. The plate was
incubated for another hour at room temperature. Luminescence signals were then read using a
standard Beta counter. Data were processed in Microsoft Excel and Graphpad Prism. Data were
globally fit in Graphpad Prism to the modified Gaddum/Schild model combined with the Hill
equation (Motulsky and Christopoulos 2004). An extra sum of squares F-test was performed
to assess whether or not the Schild and Hill slopes were significantly different from unity.
Animals
Ten-to-twelve week old male 5-HT7−/− mice and their male 5-HT7+/+ sibling controls were
used. The generation of the 5-HT7−/− mouse strain has been described previously (Hedlund et
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al. 2003). The mice used in this study had been back-crossed on a C57BL/6J background for
at least 16 generations. All behavioral experiments were started at 09.00 h. The mice were
housed in a 12-hour light/dark cycle (lights on at 06.00 and off at 18.00) and had free access
to water and food pellets. All the experiments were carried out in accordance with the Guide
for the Care and Use of Laboratory Animals as adopted and promulgated by the US National
Institutes of Health, and were approved by the Animal Care and Use Committee at The Scripps
Research Institute. Every effort was made to reduce the number of animals used and to
minimize potential suffering.
Tail suspension test
The tail suspension test was performed as previously described (Hedlund et al. 2005). Briefly,
mice were suspended from a metal rod mounted 50 cm above the surface by fastening the tail
to the rod with adhesive tape. The duration of the test was 6 minutes and immobility was
measured during the last 4 minutes to facilitate comparison with previous studies. Immobility
was defined as the absence of any limb or body movements, except those caused by respiration.
Forced swim test
The forced swim test was performed as previously described (Hedlund et al. 2005). Briefly,
mice were gently placed in a clear plastic cylinder, diameter of 16 cm, height 25 cm, filled with
10 cm of clear water at 25°C. Test duration was six minutes and immobility was measured
during the last four minutes. Immobility was defined as the absence of any horizontal or vertical
movement in the water, but excluded minor movements required for the mouse to keep its head
above the surface. The water was replaced before each animal.
Drug treatments
For the tail suspension test and forced swim test, single intra-peritoneal injections were given
30 minutes prior to the test. Amisulpride was obtained from Sigma-Aldrich. The drug was
dissolved in 50 mM tartaric acid in 0.9% NaCl and administered in the doses indicated in a
total volume of 0.2 ml. The vehicle alone was used as control.
Data analysis
All values are expressed as means ± standard errors of the mean (S.E.M.). Possible differences
between genotypes and/or drug treatments were analyzed using two-way analysis of variance
(ANOVA) with genotype as one factor and drug treatment as the other factor. The ANOVA
was followed by an appropriate Bonferroni post test. All analyses were performed using the
GraphPad Prism software package. Differences were considered significant at P < 0.05.
Results
Amisulpride has high affinity for human 5-HT7a receptors
In order to identify targets that might explain the antidepressant efficacy of amisulpride, we
undertook a large screen of potential targets using our receptorome profiling approach
(Armbruster and Roth 2005) (Table 1). Our screen confirmed that amisulpride was potent and
selective at D2 and D3 dopamine receptors. Amisulpride bound D2 receptors with a Ki of 3 ±
1 nM and D3 receptors with a Ki of 3.5 ± 0.5 nM. However, amisulpride also had high affinity
for two previously unidentified targets. These were the 5-HT2B serotonin receptor, which
bound amisulpride with a Ki of 13 ± 1 nM, and the 5-HT7a serotonin receptor, at which
amisulpride had a Ki of 11.5 ± .7 nM against [3H]LSD, which has a reported Kd of 6.6 nM for
5-HT7a receptors (Shen et al. 1993), (Roth et al. 1994) (Figure 1). Amisulpride had low affinity
for h5-HT1A serotonin receptors and other molecular targets implicated in antidepressant drug
actions (Roth et al. 2004).
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Amisulpride is a potent human 5-HT7a receptor antagonist
Our initial screen identified the h5-HT7a serotonin receptor as a high affinity target of
amisulpride. Multiple splice variants of the 5-HT7 receptor have been shown to exist in rodent
and human (Heidmann et al. 1997), and it has been shown that 5-HT7a is by far the most
common isoform in vivo in rats, though the different variants are indistinguishable in terms of
5-HT affinity and potency (Heidmann et al. 1998). Since drugs appear to exhibit identical
pharmacological characteristics at the different 5-HT7 splice variants, we performed all
amisulpride screening and characterization at the most highly expressed variant, 5-HT7a. We
elaborated on our findings by performing another set of competition assays, this time competing
amisulpride against [3H]5-CT, which has sub-nanomolar affinity for 5-HT7a receptors
(Thomas et al. 1998), (To et al. 1995) (Figure 2). [3H]5-CT preferentially labels the high-
affinity, agonist state of the receptor, while [3H]LSD, a weak partial agonist, labels mostly low
affinity, antagonist sites. We predicted that if amisulpride was a 5-HT7a receptor antagonist,
it should have preferentially lower affinity for [3H]5-CT labeled vs [3H]LSD sites. Indeed,
amisulpride had a much lower affinity for [3H]5-CT-labeled 5-HT7a receptors (Ki = 135.5 ±
15.8 nM), suggesting that it is an antagonist. In confirmation of this finding, initial studies
indicated that amisulpride did not induce cAMP accumulation (data not shown). Next, we
generated dose response curves for 5-HT activation of 5-HT7a receptors in the absence or
presence of increasing concentrations of amisulpride, the putative antagonist. We then used
non-linear least squares regression to globally fit the dose response curves to the modified
Gaddum/Schild equation (Motulsky and Christopoulos 2004). As can be seen, increasing
concentrations of amisulpride shifted the dose response curve for 5-HT activation of 5-HT7a
receptors to the right in a parallel fashion, suggesting that amisulpride is a reversible,
competitive antagonist (Figure 3). An extra sum of squares F-test determined that the Schild
slope was not significantly different from a value of 1, which indicates that amisulpride is a 5-
HT7a receptor competitive antagonist. The pA2 (7.94 ± .08) derived from globally fitting the
Gaddum/Schild equation thus provides an estimate of the Kd (11.4 ± .8 nM) which is consistent
with our earlier Ki affinity estimates at the [3H]LSD labeled receptor sites. Thus, we have
established that amisulpride is a high affinity competitive antagonist at the 5-HT7a receptor.
The 5-HT7 receptor mediates the antidepressant effects of amisulpride in vivo
Our identification of the 5-HT7a receptor as a novel target for amisulpride suggested that 5-
HT7 receptors might be the target mediating its antidepressant actions in vivo. We predicted
that, if 5-HT7 receptors were the critical mediator of the antidepressant effects of amisulpride,
then amisulpride should lack antidepressant efficacy in 5-HT7−/− mice. As previously reported
(Hedlund et al. 2005) (Guscott et al. 2005), 5-HT7−/− mice showed lower immobility time than
5-HT7+/+ mice in the tail suspension test (TST) and the forced swim test (FST) when given
vehicle only. Amisulpride displayed a U-shaped dose-response effect in 5-HT7+/+ mice (Figure
4) in both the TST and the FST, though the effective dose of amisulpride was different in the
two depression models. In 5-HT7+/+ mice the immobility time was significantly reduced at 1
mg/kg in TST and 0.1 mg/kg in FST, which is consistent with the expected antidepressant
effect of the drug. On the other hand, amisulpride in doses less than 10 mg/kg in TST and less
than 1 mg/kg in FST did not affect immobility in 5-HT7−/− mice (i.e., exerted no antidepressant
efficacy). At 10 mg/kg of amisulpride in TST and 1 mg/kg in FST, the immobility response
was significantly increased in 5-HT7−/− mice to the level of 5-HT7+/+ mice, likely due to extra-
pyramidal actions at these higher doses. Similarly, the clear antidepressant effect disappears
at higher doses (3 and 10 mg/kg in TST and .3 and 1 mg/kg in FST) in 5-HT7+/+ mice. This
low dose antidepressant effect of amisulpride is consistent with the clinical literature (Racagni
et al. 2004).
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The main findings of this paper are that amisulpride is a potent 5-HT7a receptor antagonist and
that its antidepressant actions (as assessed by the TST) require functional 5-HT7 receptors in
vivo. The unique therapeutic profile of amisulpride has proven difficult to explain in light of
its known pharmacological profile. There is some evidence that amisulpride has some
selectivity for presynaptic dopamine autoreceptors, and exhibits limbic versus striatal
selectivity, particularly at low doses, and it has been suggested that this might account for its
therapeutic profile (Schoemaker et al. 1997). It should be noted, however, that haloperidol has
similar effects at presynaptic dopamine autoreceptors, while another benzamide derivative,
sulpride, also exhibits virtually identical limbic selectivity (Schoemaker et al. 1997). Sulpride,
which exhibits similar D2/D3 selectivity when compared to amisulpride, and the related
substituted benzamides raclopride, remoxipride, and metoclopramide, do not bind to 5-HT7
receptors (Roth et al. 1994). Sulpride has a very small antidepressant effect in humans, despite
an apparently similar pharmacological profile to amisulpride (Drago et al. 2000). It also appears
to have a depressant effect when given in conjunction with an antidepressant in rat models of
depression, as it leads to a substantial reinstatement of depression (Cervo and Samanin
1987). The evidence that antidepressants modulate dopamine levels in prefrontal cortex (Tanda
et al. 1994) further suggests that dopamine may play some role in mediating their efficacy,
though little to no evidence exists that modulation of dopaminergic signaling is sufficient or
necessary for amisulpride’s antidepressant actions.
Indeed, the only antidepressant for which any case can be made for a solely dopaminergic mode
of action is amisulpride, due to its apparent selectivity for D2/D3 receptors and well established
clinical antidepressant efficacy. Given the inconsistency of the literature with respect to the
effect of dopaminergic agents on depression, and the known lack of antidepressant efficacy of
other closely related benzamides, we hypothesized that some other target might explain the
antidepressant actions of amisulpride. We thus began by performing a parallel screen at a large
panel of cloned receptors with the aim of identifying a hitherto unidentified target for
amisulpride. The results of our screen were consistent with a previous screen (Schoemaker et
al. 1997) in indicating that amisulpride is relatively selective for D2/D3 receptors. We identified
two previously unreported targets, however: 5-HT2B and 5-HT7a. Agonists at the 5-HT2B
receptor have been associated with cardiac valvulopathy (Rothman et al. 2000), (Roth 2007),
(Berger et al. 2009), while 5-HT2B antagonists such as amisulpride (Huang et al, submitted)
appear to be safe. There is no evidence that 5-HT2B receptors can mediate any therapeutic
actions of amisulpride. On the other hand, the 5-HT7 receptor (Shen et al. 1993), (Lovenberg
et al. 1993), (Bard et al. 1993) has been consistently implicated in numerous studies in the
etiology of circadian rhythm regulation, mood, sleep architecture, thermoregulation,
depressive behaviors (Hedlund and Sutcliffe 2004), (Berger et al. 2009), and antipsychotic
drug actions (Roth et al. 1994), making it a promising candidate target for mediating the
antidepressant effects of amisulpride.
Indeed, we found that amisulpride is a potent competitive 5-HT7a receptor antagonist. We thus
hypothesized that antagonism of 5-HT7a receptors was likely to be responsible for the
antidepressant efficacy of amisulpride. To test this hypothesis, we used an in vivo approach,
predicting that amisulpride would no longer be efficacious in mice in which the 5-HT7 receptor
has been genetically deleted. As expected, low dose amisulpride had no antidepressant effect
in the TST and FST in 5-HT7−/− mice, despite its efficacy in 5-HT7+/+ littermates. This is
unlikely to be due to a “floor effect” in 5-HT7−/− mice resulting from their lower baseline
immobility time, as it has been shown that citalopram, an SSRI antidepressant, reduces TST
immobility time in both 5-HT7+/+ and 5-HT7−/− mice (Hedlund et al. 2005). The roughly 25%
reduction in TST immobility time seen in 5-HT7+/+ mice after treatment with amisulpride is
consistent with the previously reported effect of the 5-HT7 antagonist SB269970 in TST, and
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not as large as the 50% or greater reduction seen with the SSRI citalopram (Hedlund et al.
2005). Finally, the increase in immobility time at higher doses of amisulpride is consistent with
the reported immobility-increasing effects of the D2/D3 antagonist (−)eticlopride in TST
(Ferrari and Giuliani 1997), which further suggests that D2/D3 antagonism cannot explain the
antidepressant efficacy of amisulpride. Thus, the clear conclusion is that 5-HT7 receptors are
critical mediators of the antidepressant actions of amisulpride in vivo in the TST and FST, the
best established animal models of depression.
Studies of the effects of drugs that target 5-HT7 receptors are highly consistent with our
hypothesis. As shown previously and in this study, 5-HT7−/− mice exhibit significantly less
immobility time in the TST (Hedlund et al. 2005) and FST (Hedlund et al. 2005), (Guscott et
al. 2005), which is consistent with the idea that reducing 5-HT7 receptor signaling has
antidepressant effects. While SB269970, a selective 5-HT7 receptor antagonist, reduced
immobility time in the TST and FST in 5-HT7+/+ mice, it had no effect in 5-HT7−/− mice
(Hedlund et al. 2005). This antidepressant effect of SB269970 in TST and FST has been
confirmed in at least one other study (Wesolowska et al. 2006). Finally, another 5-HT7
antagonist, SB258719, has been shown to reduce immobility time in FST (Guscott et al.
2005).
It is worth noting that chronic fluoxetine treatment has been shown to downregulate 5-HT7
receptors in the hypothalamus (Sleight et al. 1995), (Mullins et al. 1999), thus correlating
antidepressant efficacy with changes in 5-HT7 receptor signaling, further evidence that a
reduction in 5-HT7 receptor signaling may be beneficial with respect to treating depression.
Another important physiological parameter that is affected by antidepressant treatment is sleep.
Changes in sleep architecture have long been known to be associated with depression.
Depressed subjects exhibit shorter latency time to the first entry into rapid eye movement
(REM) sleep and increased total REM sleep time (Brunello et al. 2000). Most antidepressants
normalize sleep architecture problems, increasing REM latency and decreasing total REM
sleep time (Staner et al., 1999). The ability of antidepressants to normalize the sleep architecture
abnormalities seen in depressed patients has been positively associated with clinical response
in a number of studies, though a few studies have been unable to replicate this finding (Ott et
al. 2002). Not surprisingly, the 5-HT7 receptor antagonist SB-656104-A initiates REM sleep
changes consistent with those caused by most SSRI and tricyclic antidepressants, increasing
latency to the start of REM sleep and decreasing total REM sleep time (Thomas et al. 2003).
Furthermore, 5-HT7−/− mice spend less time in REM sleep (Hedlund et al. 2005). Finally, there
is some evidence that 5-HT7 receptor antagonism may affect neuronal morphology (Kvachnina
et al. 2005) and stimulate hippocampal neurogenesis alone (Nandam et al. 2007), (Kodama et
al. 2004) or synergistically with another antidepressant (Xu et al. 2006). This is consist with
antidepressant activity, since antidepressant efficacy has been correlated with hippocampal
neurogenesis in some (Santarelli et al. 2003), (Malberg et al. 2000), but not all (Holick et al.
2008), studies. Thus, 5-HT7 receptor antagonists initiate a number of the same physiological
changes as commonly prescribed SSRI and tricyclic antidepressants.
The prevailing notion that amisulpride exerts its well established clinical antidepressant effects
by antagonizing D2/D3 receptors results primarily from two lines of reasoning. First, an early
screen of amisulpride showed that amisulpride appeared to be selective for D2/D3 receptors,
suggesting that any therapeutic efficacy of the drug must be mediated by that action. Second,
a number of studies have shown that antidepressants affect dopamine and dopamine receptors,
leading to the hypothesis that changes in the dopaminergic system may be an important
component of antidepressant drug actions (Dailly et al. 2004). Nonetheless, the idea that the
antidepressant effects of amisulpride are mediated via D2/D3 antagonism is problematic for a
number of reasons. First, and perhaps most prominently, no other D2/D3 antagonist, including
other benzamide derivatives, appears to be a highly effective antidepressant in either animal
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models or humans. Second, though the evidence is strong that there are dopaminergic changes
in response to antidepressant treatment, nothing indicates that these phenomena are crucial for
antidepressant actions.
Our identification of the 5-HT7a receptor as a target blocked by amisulpride suggests a plausible
explanation for its antidepressant efficacy. Changes in 5-HT7 receptor function have been
shown to result from chronic antidepressant treatment (Sleight et al. 1995), (Mullins et al.
1999). Furthermore, 5-HT7−/− mice exhibit less immobility time in the TST and FST when
compared to their littermates (Hedlund et al. 2005), (Guscott et al. 2005) and 5-HT7a receptor
antagonists are effective in animal models of depression (Hedlund et al. 2005) and have the
same effects on sleep architecture as most antidepressants (Hedlund et al. 2005), (Wesolowska
et al. 2006). 5-HT7 receptor antagonists and presently approved antidepressants also appear to
have similar effects on hippocampal neurogenesis (Kvachnina et al. 2005). Finally, many
antidepressant drugs bind 5-HT7 receptors with high affinity, suggesting the possibility that
actions at 5-HT7 receptors may therapeutically complement the antidepressant efficacy of their
other pharmacological activities, thereby enhancing their efficacy (Shen et al. 1993). Thus,
there are multiple lines of evidence suggesting that 5-HT7a receptors might be mediating the
antidepressant effects of amisulpride in vivo. Our data showing that amisulpride has no
antidepressant effect in 5-HT7−/− mice makes any other conclusion as to the mechanism of
action of the antidepressant efficacy of amisulpride highly problematic. Additionally, the
finding that amisulpride is a highly effective antidepressant via antagonism at 5-HT7 receptors
would make its mechanism of action a unique one relative to other approved antidepressant
drugs and supports the development and/or testing of more selective 5-HT7 receptor antagonists
to treat depression in humans.
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Amisulpride (▲) and chlorpromazine (■) versus [3H]LSD competition binding at 5-HT7a
receptors. Amisulpride competes effectively against the high affinity 5-HT7a antagonist
chlorpromazine at cloned h5-HT7a receptors, suggesting that it binds with high affinity to 5-
HT7a receptors.
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Amisulpride (▲) and 5-HT (■) versus [3H]5-CT competition binding at 5-HT7a receptors. The
comparatively low affinity of amisulpride for [3H]5-CT, a 5-HT7a agonist with high intrinsic
activity that preferentially binds high affinity sites, in contrast with its higher affinity for [3H]
LSD, a very weak partial agonist that labels primarily low affinity antagonist binding sites,
suggests that amisulpride is an antagonist at 5-HT7a receptors.
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The modified Gaddum/Schild equation-fitted dose response data for 5-HT activation of 5-
HT7a receptors in the presence of 0, 1, 3, 10, 30, 100, and 300 nM amisulpride. All dose response
data generated in the presence of all seven amisulpride concentrations were fitted to generate
the curves shown: 0, 10, 30, and 100 nM amisulpride. There appears to be a parallel, rightward
shift of the dose response curves in the presence of increasing concentrations of amisulpride,
suggesting that amisulpride is a competitive antagonist at 5-HT7a receptors.
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Dose-response effect of amisulpride on the immobility profile of 5-HT7+/+ (□) and 5-HT7−/−
(■) mice in (upper panel) the tail suspension test and (lower panel) the forced swim test.
Amisulpride shows a dose-dependent antidepressant efficacy in both depression models by
reducing immobility time in 5-HT7+/+ but not 5-HT7−/− mice. Values are mean ± SEM. n = 6
animals per genotype per treatment group. *p < 0.05, **p < 0.01, ***p<0.001 between the
genotypes; †p < 0.05, †††p < 0.001 within a genotype compared to control; two-way ANOVA
followed by Bonferroni's post-hoc test.
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Table 1
Ki estimates for amisulpride at a large panel of cloned receptors




5-HT1A > 10,000 nM .5 nM [3H]8-OH-DPAT SBB 1.5 hours
5-HT1B 1744 ± 199 nM .3 nM [3H]5-CT SBB 1.5 hours
5-HT1D 1341 ± 217 nM .3 nM [3H]5-CT SBB 1.5 hours
5-HT1E > 10,000 nM 3 nM [3H]5-HT SBB 1.5 hours
5-HT2A 8304 ± 1579 nM .5 nM [3H]ketanserin SBB 1.5 hours
5-HT2B 13 ± 1.12 nM 1.1 nM [3H]LSD SBB 1.5 hours
5-HT2C > 10,000 nM .5 nM [3H]N-methyl-mesulergine SBB 1.5 hours
5-HT3 > 10,000 nM .29 nM [3H]LY278584 SBB 1.5 hours
5-HT5A > 10,000 nM 1 nM [3H]LSD SBB 1.5 hours
5-HT6 4154 ± 599 nM 1.05 nM [3H]LSD SBB 1.5 hours
5-HT7 11.5 ± .71 nM 1.05 nM [3H]LSD SBB 1.5 hours
5-HT7a 135.5 ± 15.8 nM .35 nM [3H]5-CT SBB 1.5 hours
α1a > 10,000 nM .1 nM [125I]HEAT A1BB 1 hour
α1b > 10,000 nM .1 nM [125I]HEAT A1BB 1 hour
α1d > 10,000 nM .1 nM [125I]HEAT A1BB 1 hour
α2a 1114 ± 124 nM .1 nM [125I]clonidine A2BB 1 hour
α2c 1540 ± 171 nM .1 nM [125I]clonidine A2BB 1 hour
β1 > 10,000 nM .1 nM [125I]iodopindolol BBB 1 hour
β2 > 10,000 nM .1 nM [125I]iodopindolol BBB 1 hour
β3 > 10,000 nM .1 nM [125I]iodopindolol BBB 1 hour
Benzodiazapene > 10,000 nM .5 nM [3H]flunitrazepam BZPBB 1.5 hours
D1 > 10,000 nM .21 nM [3H]SCH23390 DBB 1.5 hours
D2 3 ± 1 nM .19 nM [3H]N-methyl-spiperone DBB 1.5 hours
D3 3.5 ± .5 nM .35 nM [3H]N-methyl-spiperone DBB 1.5 hours
D4 2369 ± 608 nM .19 nM [3H]N-methyl-spiperone DBB 1.5 hours
D5 > 10,000 nM .21 nM [3H]SCH23390 DBB 1.5 hours
DOR > 10,000 nM .3 nM [3H]DADLE SBB 1.5 hours
KOR > 10,000 nM .3 nM [3H]U69593 SBB 1.5 hours
MOR > 10,000 nM .3 nM [3H]DAMGO SBB 1.5 hours
H1 > 10,000 nM .9 nM [3H]pyrilamine HBB 1.5 hours
H2 > 10,000 nM 3 nM [3H]tiotidine HBB 1.5 hours
H4 > 10,000 nM 5 nM [3H]histamine HBB 1.5 hours
M1 > 10,000 nM .5 nM [3H]QNB MBB 1.5 hours
M2 > 10,000 nM .5 nM [3H]QNB MBB 1.5 hours
M3 > 10,000 nM .5 nM [3H]QNB MBB 1.5 hours
M4 > 10,000 nM .5 nM [3H]QNB MBB 1.5 hours
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M5 > 10,000 nM .5 nM [3H]QNB MBB 1.5 hours
DAT > 10,000 nM .5 nM [3H]WIN35428 TBB 1.5 hours
NET > 10,000 nM .5 nM [3H]nisoxetine TBB 1.5 hours
SERT > 10,000 nM .5 nM [3H]citalopram TBB 1.5 hours
EP3 > 10,000 nM .5 nM [3H]PGE2 PBB 1.5 hours
EP4 > 10,000 nM .5 nM [3H]PGE2 PBB 1.5 hours
σ1 > 10,000 nM 3 nM [3H]pentazocine SigmaBB 2.5 hours
σ2 > 10,000 nM 3 nM [3H]DTG SigmaBB 2.5 hours
Standard Binding Buffer (SBB): 50 mM Tris HCl, 10 mM MgCl2, 0.1 mM EDTA, pH 7.4
Dopamine Binding Buffer (DBB): 50 mM HEPES, 50 mM NaCl, 5 mM MgCl2, 0.5 mM EDTA, pH 7.4
Histamine Binding Buffer (HBB): 50 mM Tris HCl, 0.5 mM EDTA, pH 7.4
Transporter Binding Buffer (TBB): 50 mM Tris HCl, 150 mM NaCl, 5 mM KCl, pH 7.4
Prostaglandin Binding Buffer (PBB): 25 mM Tris HCl, 10 mM MgCl2, 1 mM EDTA, pH 7.4
Alpha1 Binding Buffer (A1BB): 20 mM Tris HCl, 145 mM NaCl, pH 7.4
Alpha2 Binding Buffer (A2BB): 50 mM Tris HCl, 5 mM MgCl2, pH 7.7
Beta Binding Buffer (BBB): 50 mM Tris HCl, 3 mM MnCl2, pH 7.7
Muscarinic Binding Buffer (MBB): 50 mM Tris HCl, pH 7.7
Sigma Binding Buffer (SigmaBB): 50 mM Tris HCl, pH 8.0
Benzodiazapene Binding Buffer (BZPBB): 50 mM Tris HCl, 2.5 mM CaCl2, pH 7.4
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